MELANOCORTIN AGENTS FOR TUMOR THERAPY
BV22Gastrointestinal TumorsMelanocortin AntagonistsMelanomaoncologyThyroid cancer
Introduction
The present invention falls within the field of therapeutic treatments of tumor pathologies, particularly solid tumors, such as melanoma, gastrointestinal tract tumors and thyroid carcinoma. The usage of a melanocortin receptor 4 antagonist provides a new possible target therapy for the treatment of cancer, reducing the risk of its recurrence.
Technical features
Melanocortin receptor 4 antagonists (MC4R) have been tested and widely studied in the therapeutic treatment of tumor pathologies, such as melanoma, tumors of the gastrointestinal tract and thyroid carcinoma. These tumor types, presenting a substantial incidence of recurrence, can benefit from alternative treatments: few pharmacological therapies, in addition to radiotherapy, are available for instance for thyroid carcinoma. MC4R antagonists are suitable for use in targeted anti-tumor treatment, particularly in adjuvant therapy or in therapy that influences the onset and/or progression of tumor metastases. Thus, our target approach can reduce the side effect of that targeted therapy, which uses cytotoxic drugs.
Furthermore, a pharmaceutical composition has been formulated, comprising a melanocortin receptor 4 (MC4R) antagonist in a pharmaceutically acceptable carrier, as well as in combination with any adjuvants, stabilizers and/or preservatives.
Furthermore, a pharmaceutical composition has been formulated, comprising a melanocortin receptor 4 (MC4R) antagonist in a pharmaceutically acceptable carrier, as well as in combination with any adjuvants, stabilizers and/or preservatives.
Possible Applications
- Treatment of tumors expressing the melanocortin receptor 4;
- Targeted treatment with melanocortin receptor 4 antagonists of a tumor pathology, such as melanoma, tumors of the gastrointestinal tract and thyroid carcinoma;
- Application in adjuvant therapy;
- Application in metastatic disease therapy.
Advantages
- Combination treatment with reduced dose of the antineoplastic drugs;
- Increased and improved therapeutic efficacy;
Reduction of the toxicity of antineoplastic treatments;- Reduction of the possibility of recurrence.